Media stories about Neuralstem (NASDAQ:CUR) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neuralstem earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.9614675568422 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Neuralstem (NASDAQ CUR) opened at 1.11 on Tuesday. Neuralstem has a 12-month low of $0.20 and a 12-month high of $6.60. The stock has a 50 day moving average of $3.89 and a 200 day moving average of $4.40. The company’s market cap is $13.21 million.

Neuralstem (NASDAQ:CUR) last released its earnings results on Tuesday, August 8th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.49) by $9.10. Neuralstem had a negative net margin of 198,573.91% and a negative return on equity of 321.78%. Equities analysts expect that Neuralstem will post ($2.26) earnings per share for the current year.

Separately, ValuEngine raised shares of Neuralstem from a “sell” rating to a “hold” rating in a report on Friday, June 9th.

TRADEMARK VIOLATION NOTICE: “Neuralstem (NASDAQ:CUR) Getting Somewhat Favorable Media Coverage, Report Shows” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at

In other news, CEO Richard J. Daly bought 7,500 shares of the stock in a transaction that occurred on Wednesday, May 17th. The shares were bought at an average price of $4.00 per share, for a total transaction of $30,000.00. Following the purchase, the chief executive officer now owns 23,312 shares in the company, valued at $93,248. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 15.43% of the stock is currently owned by insiders.

Neuralstem Company Profile

Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

Insider Buying and Selling by Quarter for Neuralstem (NASDAQ:CUR)

Receive News & Stock Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related stocks with our FREE daily email newsletter.